MedTrace Logo

Autologous Blood Transfusion After Local Infiltration

NCT01576263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2015-04-10

No results posted yet for this study

Summary

Total knee and hip arthroplasty for osteoarthritis is performed on still broader indications even in elderly patients with previous or current medical conditions. Especially comorbidity like cardiovascular diseases and conditions with increased risk of bleeding or previous thrombo-embolic events are major challenges.

To facilitate safe use of ropivacaine as an analgesic, information on the concentrations levels after autologous blood transfusion following local infiltration analgesia is very crucial. However, very limited data are available. To verify the safety of autologous blood transfusion, ropivacaine concentrations were studied in 52 patients undergoing either total knee arthroplasty or total hip arthroplasty.

Conditions

  • Total Hip Arthroplasty
  • Total Knee Arthroplasty

Interventions

DRUG

Autologous blood transfusion with ropivacaine

Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg

DRUG

Autologous blood transfusion with ropivacaine

Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.

Sponsors & Collaborators

  • Northern Orthopaedic Division, Denmark

    lead OTHER

Principal Investigators

  • Ole Simonsen, M.D. · Northern Orthopaedic Department, Aalborg University Hospital, Denmark

  • Sten Rasmussen, M.D. · Northern Orthopaedic Division, Aalborg University Hospital, Denmark

  • Bjarne B. Dencker, M.D. · Department of Anaesthesiology, Aalborg University Hospital, Denmark

  • Torben Breindahl, M.D. · Department of Clinical Biochemistry, Vendsyssel Hospital, Aarhus University, Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-04-30
Completion
2010-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01576263 on ClinicalTrials.gov